Amgen Inc.

Equities

AMGN

US0311621009

Real-time Estimate Cboe BZX Other stock markets 17:32:26 23/01/2026 GMT			5-day change	1st Jan Change
343.94 ^USD	-0.90%		+4.49%	+5.48%

02:00pm	The Market's Favorite Question Right Now: Is This a Return to Normal, or Just a Pause?
10:47am	Bernstein Downgrades Amgen to Market Perform From Outperform, Price Target is $335	MT

Transcript : Amgen Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 10

Published on 12/03/2025 at 04:35 pm GMT - Modified on 12/03/2025 at 10:05 pm GMT

S&P Capital IQ

Presenter Speech
Umer Raffat (Analysts)

Very excited to have Amgen management with us. I'll let you guys kick things off and we'll jump right in.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Amgen Inc.

02:00pm	The Market's Favorite Question Right Now: Is This a Return to Normal, or Just a Pause?
10:47am	Bernstein Downgrades Amgen to Market Perform From Outperform, Price Target is $335	MT
09:24am	Analyst recommendations: Amgen, P&G, Spotify, Duolingo, Moderna…
01-22	MBX Biosciences, Inc. Announces Board and Committee Changes	CI
01-20	Global drugmakers rush to boost US presence as tariff threat looms	RE
01-15	Espiria Hållbar Framtid Rises 0.4 Percent in December — Increased Holdings in Epiroc and Afry	FW
01-14	Honeywell Says Quantinuum Plans Confidential Filing of IPO Draft Registration	MT
01-13	Ro partners with Amgen to study barriers to obesity care, GLP-1 access	RE
01-13	Ro partners with Amgen to study barriers to obesity care, GLP-1 access	RE
01-13	Analyst recommendations: JPMorgan, Meta, Citigroup, BlackRock, AbbVie…
01-13	Aligos Therapeutics, Inc. Appoints James Hassard as Executive Vice President and Chief Commercial Officer, Effective January 13, 2026	CI
01-13	Alert incorrectly tagged to Rubicon Organics withdrawn	RE
01-13	The CPI That Changed Almost Nothing
01-13	Ro announces research collaboration with Amgen to evaluate real-world GLP-1 coverage	RE
01-13	Global drugmakers rush to boost US presence as tariff threat looms	RE
01-13	Amgen's Extension Study Shows MariTide Helped Maintain Weight Loss at Lower Dose, Less Frequency	MT
01-13	Focus on inflation and corporate earnings
01-13	Amgen Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 03:45 PM
01-13	Amgen says MariTide helped trial patients maintain weight loss	RE
01-13	Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weight	RE
01-12	Amgen: Second year of Maritide treatment very well tolerated including at quarterly doses, with very low incidence of nausea, vomiting & no new safety signals observed	RE
01-12	Amgen: "Large majority" of people in 52-week Maritide extension study given lower monthly dose or quarterly dose of drug maintained weight loss achieved in part 1 of phase 2 trial	RE
01-12	Amgen says 24-week study of monthly Maritide in people with type 2 diabetes showed robust, clinically meaningful reduction in both HbA1c, weight	RE
01-12	Amgen to announce data on obesity drug MariTide at healthcare conference	RE
01-12	BioMarin Pharmaceutical Names Arpit Dave Chief Digital and Information Officer	MT